SU111934A1 - The method of obtaining the drug splenin for the treatment of toxicosis in early pregnancy - Google Patents

Description

A method for the preparation of the drug Splenin, which is an agent for the treatment of toxicosis in early pregnancy and a prophylactic agent, is proposed to prevent the transition of the lungs of the initial forms of toxicosis to a more severe form.

The drug splenin was prepared as follows.

100 kg of the crushed mass of the spleen, aged for three days at a temperature of 5-6 ° and loaded into the extraction apparatus, pour 200 kg of dichloroethane. The apparatus is closed and the mass is extracted for 6-8 days at a temperature of 15-18 °.

In the first four hours, extraction is carried out with a continuously operating mixer, and on the following days the mass is mixed in the extractor for at least 15 minutes every hour. In total, the splenic mass should be moved per day for at least 6 hours.

On the last day of extraction, the supernatant extract (dichloroethane, as heavier, will be at the bottom and the splenic mass at the top) will be released from the extraction apparatus through a tap, which should be located at the lowest point of the apparatus, and filtered through a suction filter into the bottle.

To re-extract the remaining mass of the spleen, 100 kg of dichloroethane is poured. Extraction is performed under conditions similar to the first and lasts 48 hours. After that, the extract is released through the suction filter into the bottle and mixed with the first-mother extract.

To separate dichloroethane from the splenic mass, both after the first and second extraction, the extract is passed through a supercentrifuge. Centrifugation and filtration are adjusted so that the centrifuged extract immediately passes through the suction filter into the bottle. The combined dichloroethane extract from the first and second extraction is poured into a vacuum apparatus and subjected to distillation at a temperature not higher than 45 ° to a volume of 4-5 liters, and then transferred into a glass flask and distilled to until the very last removal of dichloroethane.

The remaining mass in the flask after distillation of dichloroethane is heated with a 10–15 ppm water vapor. at a temperature of 40 °, dissolve in 2000 ml of 70 ° ethyl alcohol and pour into the bottle, carefully washing the contents of the flask with alcohol.

The alcoholic solution contains splenin and ballast substances, to remove which 1500 ml of petroleum ether are added. After 10-minute stirring on a shtatel apparatus, the solution is transferred to a dividing funnel and allowed to stand. The alcohol fraction containing the splenum is located at the bottom of the separatory funnel. The fraction is then transferred to a flask, treated again in the same manner with the addition of 500 ml of petroleum ether and again separated and decanted in a separatory funnel.

To the remaining combined ether fraction, 500 g of 70 ° ethyl syirt are added and shaken again for 10 minutes. for the extraction of active substances, which can partly be lost in the ether fraction. The alcohol fraction is drained and combined with the first, and the ether fraction, in which the ballast substances are contained, is removed or transferred to regeneration.

The alcohol-water fraction in which the spleiin is contained is transferred to a flask and concentrated under vacuum at a temperature not higher than 45 ° until the alcohol is completely removed.

The aqueous residue is measured, transferred to a flask, and chemically pure table salt is added from such a calculation so that the aqueous residue contains 0.85% sodium chloride, shaken until complete dissolution of the table salt and set to

3-4 hours in a bowl of ice mixed for better cooling with table salt.

The flask with splenin is removed, allowed to stand at room temperature for 4 to 6 hours (until the solution is warmed to room temperature), and then filtered through a filter paper.

The aqueous residue containing splenn is diluted with a physiological solution such that 1 ml of the preparation of splennum corresponds to 40 g of the spleen, ethyl alcohol is added, calculated so that the total amount of the solution contains no more than 10% ethyl alcohol, which serves as a preservative.

Splenin is poured into large Petri dishes, irradiated with a Bach mercury-quartz lamp for 15 minutes at a distance of 70 cm, periodically, every 5 minutes, placed with a glass rod, poured into an orange glass bottle and adjusted to pH 4-6.0.

Splenin is filtered through a Seitz filter and, after testing for sterility, is poured into sterile, preferably orange from neutral glass ampoules of 1-2 ml each.

The product, poured into ampoules, is again checked for sterility. After that, the finished ampoules are monitored for tightness by shaking, scanned with an optical reflector (particle suspension) and transferred to the packaging.

The decorated product is transferred for storage in the storage room. Splenin should be stored in a dark, cool place.

The drug is approved for use in medical practice by the Pharmacological Committee of the USSR Ministry of Health.

Subject invention

The method of obtaining drug splenin for the treatment of toxicosis

during early gestation, alcohol is distilled off, and the remaining water is distinguished by the fact that chemically ground spleen mass is added to the chemically ground spleen mass, clean salt, diluted cattle are extracted with physiological solution dichloroethane, the extract after clearing is calculated to 1 ml of prep-release from the organic solution corresponded to 40 g of the spleen, the solvent is treated with ethyl canned ethyl alcohol, and with non-trailing ether, the ether fraction is removed by irradiation with a quartz lamm and the ether fraction is removed. The pH is adjusted to 4-6.0.

- 3-A 111934